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Abstract Background Increased plasma levels of soluble adhesion molecules are associated with an
increased risk of atherothrombosis. The pathophysiological mechanisms responsible for
these associations are not known. The aim of the present study was to investigate the
association of soluble intercellular adhesion molecule-1 (sICAM-1) concentration and risk
of cardiovascular and all-cause mortality among individuals with and without type 2
diabetes. In addition, we assessed potential pathophysiological mechanisms by which
sICAM-1 may promote mortality.
Materials and methods Six hundred and thirty-one subjects taken from a general
population of the middle-aged and elderly participated in this prospective cohort study.
Baseline data collection was performed from 1989 to 1992; subjects were followed until 1
January 2000.
Results Subjects who died had higher levels of sICAM-1 than those who survived
(506(164) vs. 477(162) ng mL21, respectively). After adjustment for age, gender and
glucose tolerance status, subjects with sICAM-1 levels in the upper quartile
($550 ng mL21) had a relative risk of cardiovascular mortality of 2·05 (95% confidence
interval, 1·10–3·81) compared to subjects with sICAM-1 levels in the other quartiles.
Further adjustment for classical cardiovascular risk factors or indicators of (sub)clinical
atherosclerosis, endothelial dysfunction, inflammation and renal function did not
materially alter this relative risk. A high sICAM-1 level was more frequent in subjects
with type 2 diabetes than in subjects with a normal glucose tolerance (33·3 vs. 17·8%).
Conclusions Individuals with a plasma concentration of sICAM-1 higher than
550 ng mL21 had a cardiovascular mortality risk that was twice that of individuals with
a lower concentration. Classical cardiovascular risk factors (sub)clinical atherosclerosis,
endothelial dysfunction and inflammation do not explain this excess risk.
Keywords Cardiovascular mortality, pathophysiological mechanisms, soluble intercellular
adhesion molecule-1, type 2 diabetes
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Introduction
Interactions of endothelial cells and leucocytes play an
important role in leucocyte recruitment and are mediated by
adhesion molecules. Leucocyte recruitment and subsequent
transmigration into the arterial intima are early features of
atherosclerosis [1,2]. Besides selectins, membrane-bound
intercellular adhesion molecule-1 (ICAM-1) and vascular
cell adhesion molecule-1 (VCAM-1) contribute to the
adhesion of leucocytes to endothelium activated in
response to inflammatory cytokines [3]. Soluble forms of
some adhesion molecules are found in plasma; they are
shedded cell membrane ligands and may therefore be used
as a monitor of adhesion molecule expression [4,5].
Previous studies have shown an increased cellular adhesion
molecule expression in several components of the athero-
sclerotic plaque and a positive association of increased
plasma levels of soluble (s) ICAM-1 with carotid intimal-
medial thickness and cardiovascular mortality [6–8]. The
pathophysiological mechanisms linking increased plasma
sICAM-1 to atherothrombosis are unknown. Chronically
increased levels may reflect progressive formation of
atherosclerotic lesions [9]. In addition to its role in cell–
cell adhesion, ICAM-1 also serves as a receptor for soluble
fibrinogen, which suggests a role for ICAM-1 in throm-
bosis [10]. High glucose levels enhance the expression of
ICAM-1 on endothelial cells in vitro [11]. In a cross-
sectional study, levels of sICAM-1 were shown to be
higher among individuals with type 2 diabetes than among
nondiabetic individuals [12]. ICAM-1 may therefore play
a role in the accelerated macroangiopathy that is present in
individuals with type 2 diabetes [12].
The aim of the present study was to investigate the
association of sICAM-1 concentration and risk of cardi-
ovascular and all-cause mortality among individuals
without and with type 2 diabetes in a prospective
population-based cohort study. In addition, we assessed
potential pathophysiological mechanisms by which
sICAM-1 may increase mortality. Specifically, we assessed
whether sICAM-1 reflects (sub)clinical atherosclerosis (as
assessed by the ankle-brachial pressure index and the
presence of cardiovascular disease); endothelial dysfunc-
tion [as reflected by the plasma concentration of von
Willebrand factor and (micro)albuminuria]; chronic low-
grade inflammation (as reflected by the plasma concen-
tration of C-reactive protein and sVCAM-1) or a general
increase in the expression of adhesion molecules (as
reflected by the plasma concentration of sVCAM-1).
Methods
General study design
The study was performed in the Hoorn Study (the
Netherlands), a population-based cohort study of glucose
tolerance in a Caucasian population, conducted from
October 1989 to February 1992, as described in detail
before [13,14]. Briefly, a random sample of all men and
women aged 50–75 was drawn from the municipal
population registration office of Hoorn; 2484 individuals
participated (response rate 71%). The present study
population is an age-, sex- and glucose-tolerance-stratified
random subsample (n  631; response rate 89·1%), in
whom an extensive cardiovascular investigation was
performed.
Baseline investigations
SICAM-1
Concentrations of sICAM-1 were assessed in duplicate in
deep frozen (2 70 8C) heparin plasma samples. No
plasma was available for 23 subjects. Concentrations of
sICAM-1 were measured using enzyme-linked immuno-
sorbent assay (ELISA) kits [Bender MedSystems, Wenen,
Austria (Cat. no. BMS241)]. According to the manu-
facturer, the intra- and interassay coefficients of variation
for the assay were 5·6% and 7·8%, respectively.
Other measurements
We obtained an ankle-brachial blood pressure index
(n  631) and a resting electrocardiogram (n  625)
[13,14]. Subjects were classified as having cardiovascular
disease when they had a history of myocardial infarction
and/or had an electrocardiogram with a Minnesota code
1·1–1·3, 4·1–4·3, 5·1–5·3, or 7·1 and/or had undergone
coronary bypass surgery or angioplasty, and/or had an
ankle-brachial pressure index less than 0·9 in either leg
and/or had undergone a peripheral arterial bypass or
amputation. Furthermore, we obtained data on blood
pressure, weight, height, body mass index, waist-to-hip
ratio and smoking habits, glycated haemoglobin, use of
diabetes medication and serum creatinine, homocysteine,
total cholesterol, high-density lipoprotein cholesterol and
triglyceride, and urinary albumin and creatinine levels
[14–16]. Hypertension was defined as a blood pressure
$ 160 mmHg systolic and/or $ 95 mmHg diastolic and/or
the current use of antihypertensive medication. Subjects
were classified as current cigarette smokers or nonsmokers.
Creatinine clearance was calculated by the Cockroft–
Gault formula [16], and the glomerular filtration rate was
calculated according to Levey et al. [17] (Micro)albumi-
nuria was defined as an albumin-to-creatinine ratio
. 2·0 mg mmol21 [14]. Concentrations of sVCAM-1,
von Willebrand factor and C-reactive protein were
assessed as previously described [18,19].
Follow-up
Data on the subjects’ vital status on 1 January 2000 were
collected from the mortality register of the municipality of
Hoorn. Of 51 subjects who had moved out of town,
information on vital status was obtained from the new
local municipalities. For each subject, we determined
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whether or not death had occurred during follow-up, and
if so, the date at which death occurred. For all subjects
who had died, the cause of death was extracted from the
medical records of the general practitioner and the hospital
of Hoorn and classified according to the ninth edition of
the International Classification of Diseases [20]. Cardio-
vascular mortality was defined as codes 390–459 and
cancer mortality as codes 140–240. Information on cause
of death could not be obtained for 16 (15%) of the
deceased subjects and one subject was lost to follow-up.
The Hoorn Study was approved by the Ethical Review
Committee of the University Hospital Vrije Universiteit.
Written informed consent was obtained from all participants.
Statistical analyses
The associations between sICAM-1 levels and classical
cardiovascular risk factors (such as smoking and hyperten-
sion) and risk indicators [such as (micro)albuminuria and
C-reactive protein and von Willebrand factor levels] were
tested by linear regression analyses with sICAM-1 levels as
dependent variable and risk factors or indicators as
independent variables, all adjusted for age, sex and glucose
tolerance status (unless this was the variable under
consideration). To assess associations of cardiovascular
risk factors and risk indicators with risks of cardiovascular
and all-cause mortality, we performed Cox proportional
hazards multiple regression analysis, in all cases – because
of the stratification procedure – with adjustment for age,
sex and glucose tolerance status. Results are described as
relative risks (hazard ratios) with 95% confidence inter-
vals. Survival over the follow-up duration was calculated
by Kaplan–Meier curves for different groups and differ-
ences were tested by the logrank test.
Risk factors and indicators measured on a continuous
scale were used as such in the regression models, except
for levels of high-density lipoprotein cholesterol, C-
reactive protein and von Willebrand factor, and body
mass index and waist-to-hip ratio, because the association
of these variables with mortality was nonlinear. Therefore,
a low level of high-density lipoprotein cholesterol was
defined as a level below 0·9 mmol L21 [21], a high level of
von Willebrand factor or C-reactive protein was defined as
a level in the upper tertile (. 1·56 IU mL21 and
. 2·84 mg L21, respectively [19]), obesity as a body
mass index above 27 kg m22 for men and above
26 kg m22 for women [22], and a high waist-to-hip ratio
as a waist-to-hip ratio above 0·95 for men and above
0·80 for women [23]. Levels of triglyceride were log-
transformed because of a better fit to the regression model.
To assess the associations of plasma sICAM-1 concen-
tration with cardiovascular and all-cause mortality, we
performed Cox proportional hazards multiple regression
analyses. Because preliminary analyses and a previous study
[8] suggested a nonlinear association between sICAM-1
and cardiovascular death, we divided the subjects into
quartiles (n  152) according to their sICAM-1 concentra-
tion. We calculated relative risks for subjects in the highest
quartile (above 550 ng mL21) with subjects in the lower
three quartiles as the reference group. In the first model, we
adjusted for the stratification variables age, sex and glucose
tolerance. In subsequent models, we added one or more
potentially confounding risk factors, such as hypertension,
or risk indicators, specifically (micro)albuminuria and levels
of sVCAM-1, von Willebrand factor and C-reactive protein.
Two-sided P-values less than 0·05 were considered statis-
tically significant.
Results
Table 1 (the two columns on the left) shows the baseline
characteristics of the study population. Figure 1 shows the
percentage of subjects with a sICAM-1 level in the highest
quartile (. 550 ng mL21) by glucose tolerance status. A
high sICAM-1 level was more frequent in subjects with
type 2 diabetes than in subjects with a normal glucose
tolerance (33·3 vs. 17·8%). The median (interquartile
range) of sICAM-1 levels was 467 (376–550) ng mL21 in
the whole group, 443 (367–522) ng mL21 in those with a
normal glucose tolerance, 471 (363–570) ng mL21 for
those with an impaired glucose tolerance, and 492 (407–
610) ng mL21 in those with diabetes.
The mean duration of follow-up was 8·2 years (standard
deviation: 2·0 years). During follow-up, 117 (54 with type 2
diabetes) of the 631 subjects died, of whom 45 (38%; 23 with
type 2 diabetes) died of cardiovascular disease. Subjects who
died had higher levels of sICAM-1 than those who survived
(506(164) vs. 477(162) ng mL21, respectively). Table 1
(three columns on the right) shows relative risks of mortality
associated with risk factors and risk indicators.
Associations of sICAM-1 level with cardiovascular
risk factors and indicators
Table 2 shows which cardiovascular risk factors and
indicators were significantly associated with sICAM-1
levels after adjustment for age, sex and glucose tolerance
status (unless this was the variable under consideration).
SICAM-1 level and risk of mortality
Cardiovascular mortality was markedly higher among
subjects with sICAM-1 levels in the upper quartile than
among subjects with sICAM-1 levels in the lower quartiles
(Fig. 2). This figure also shows that the relationship
between sICAM-1 and cardiovascular mortality was non-
linear. Table 3 shows that, after adjustment for age, sex and
glucose tolerance status, subjects with sICAM-1 levels in the
upper quartile ($ 550 ng mL21) had a relative risk of
cardiovascular mortality of 2·05 (95% confidence interval,
1·10–3·81) compared to subjects with sICAM-1 levels in
the three lower quartiles. Further adjustment for risk factors
or risk indicators of cardiovascular disease did not materially
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alter this relative risk. Adjustment for current smoking and
the level of sVCAM-1 made the relative risk borderline
significant. The relative risk of all-cause mortality associated
with sICAM-1 levels was somewhat less than the relative risk
of cardiovascular mortality (relative risk of the upper
compared to the three lower quartiles of sICAM-1, 1·43;
95% confidence interval, 0·96–2·13; Table 3). Further
adjustment for risk factors or indicators did not substantially
affect the results (Table 3).
Additional analyses
The associations between sICAM-1 and cardiovascular
and all-cause mortality were similar in diabetic and
nondiabetic individuals. The relative risk of cardiovascular
mortality associated with sICAM-1 levels did not sub-
stantially change during follow-up. After 2 years the
relative risk was 2·37 (95% confidence interval, 0·48–
11·75); after 4 years it was 1·65 (0·53–5·08); after 6 years
it was 1·99 (0·88–4·5), and after 8·2 years it was 2·05
(1·10–3·81).
Discussion
Our data show that sICAM-1 levels are significantly
associated with risk of cardiovascular mortality. Indivi-
duals with a plasma concentration of sICAM-1 higher
Table 1 Baseline characteristics and relative risk of cardiovascular and all-cause mortality associated with risk factors or risk indicators
Risk factor or indicator
All subjects
(n  631)
Contrasts for
which relative risk
is presented
Cardiovascular
mortality
RR (95% CI)*
All-cause
mortality
RR (95% CI)*
Male gender (%) 48 yes vs. no 1·49(0·82–2·71) 1·63(1·13–2·36)
Age (year) 64 ^ 7 per 5 years increase 1·85(1·42–2·41) 1·63(1·40–1·90)
Type 2 diabetes (%) 27 yes vs. no 3·14(1·56–6·36) 2·56(1·67–3·93)
Hypertension (%) 39 yes vs. no 2·79(1·41–5·51) 1·74(1·18–2·56)
Current smokers (%) 28 yes vs. no 1·54(0·79–2·99) 1·67(1·12–2·49)
Body mass index (kg m22) 27·2 ^ 4·0 high vs. low‡ 2·07(1·03–4·18) 1·43(0·95–2·17)
Waist-to-hip ratio 0·92 ^ 0·09 high vs. low§ 1·58(0·67–3·74) 2·04(1·17–3·55)
Total cholesterol (mmol L21) 6·6 ^ 1·2 per 1·0 mmol L21 increase 1·15(0·90–1·46) 1·11(0·96–1·29)
HDL-cholesterol (mmol L21) 1·3 ^ 0·4 low vs. high¶ 3·03(1·44–6·40) 1·85(1·14–3·00)
Triglycerides (mmol L21) 1·6(1·2–2·2) per 10% increase† 1·05(0·99–1·10) 1·04(1·01–1·08)
HbA1c (% of haemoglobin) 5·9 ^ 1·3 per 1% of haemoglobin increase 1·04(0·83–1·30) 1·09(0·94–1·26)
Von Willebrand factor (IU mL21) 1·22(0·86–1·74) high vs. low** 2·22(1·21–4·09) 1·73(1·19–2·52)
C-reactive protein (mg L21) 1·75(0·83–3·80) high vs. low** 1·65(0·89–3·05) 1·39(0·95–2·04)
sVCAM-1 (ng mL21) 1383 ^ 454 per 100 ng mL21 increase 1·08(1·03–1·13) 1·03(1·00–1·07)
sICAM-1 (ng mL21) 482 ^ 163 high vs. low‡‡ 2·05(1·10–3·81) 1·43(0·96–2·13)
Homocysteine ((mol L21) 11·4(9·3–14·1) per 5 (mol/L increase 1·09(0·96–1·25) 1·07(0·96–1·19)
Microalbuminuria (%) 11 yes vs. no¶ 2·57(1·31–5·06) 1·47(0·91–2·37)
Creatinine clearance (ml min21) §§ 78·5(18·1) per 5 mL min21 increase 0·87(0·79–0·96) 0·99(0·89–1·01)
Glomerular filtration rate (ml min21)¶¶ 70·0(20·0) Per 5 mL min21 increase 0·79(0·70–0·88) 0·87(0·80–0·94)
Prior cardiovascular disease (%) 24 yes vs. no*** 3·07(1·67–5·64) 2·06(1·41–2·99)
Ankle-brachial pressure index (% , 0·90) 10·6 high vs. low††† 3·89(2·07–7·29) 2·64(1·74–3·98)
Use of diabetes medication (%) 10·6 yes vs. no 1·31(0·30–5·78) 1·77(0·54–5·81)
Data are presented as mean ^ standard deviation, percentage of the total or median (interquartile range).
HDL-cholesterol, high-density lipoprotein; HbA1c, haemogloblin-A1c; sVCAM-1, soluble vascular cell adhesion molecule-1; sICAM-
1, soluble intercellular adhesion molecule-1.
*Relative risk (RR) with 95% confidence intervals (95% CI) obtained with Cox regression analyses of cardiovascular and all-cause
mortality associated with continuous or dichotomous variables after adjustment for age, gender, glucose tolerance status (impaired
glucose tolerance and type 2 diabetes), except when this was the variable under consideration.
†log-transformed.
‡ . . vs. # 27 kg m22 for males and . vs. # 26 kg m22 for females.
§$ vs. , 0·95 for males and $ vs. , 0·80 for females.
¶ , vs. (0·9 mmol L21.
**Upper tertile vs. lower two tertiles (. 1·56 IU mL21 for vWf and . 2·84 mg L21 for CRP levels).
††Albumin-to-creatinine ratio # vs. . 2·0 mg mmol21.
‡‡Upper quartile vs. lower three quartiles (. 550 ng mL21).
§§According to the Cockroft–Gault formula.
¶¶According to Levey et al. [26].
***A history of myocardial infarction and/or Minnosota code 1·1–1·3, 4·1–4·3, 5·1–5·3 or 7·1 on the electrocardiogram, coronary
bypass operation and/or angioplasty and/or ankle-brachial pressure index , 0·90 and/or peripheral arterial bypass or amputation.
††† , vs. $ 0·90.
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than 550 ng mL21 had a cardiovascular mortality risk that
was about twice that of individuals with a lower
concentration. Moreover, the relative risk was largely
independent of cardiovascular risk factors and indicators,
and did not vary with time. After adjustment for smoking
and sVCAM-1, the relative risks were borderline signifi-
cant, but the point estimates remained similar, which
suggests that the association between sICAM-1 and
cardiovascular mortality could at most partly be explained
by smoking or sVCAM-1. Our findings are consistent with
prospective studies in healthy male physicians [8], in
healthy postmenopausal women [24], the Atherosclerosis
Risk In Communities (ARIC) cohort [25], and selected
patient groups with peripheral arterial disease [26] and
stable angina pectoris [27].
The present study is the first to assess the association
between a high plasma concentration of sICAM-1 and the
risk of cardiovascular death with adjustment for clinical
and subclinical cardiovascular disease, and to examine
potential pathophysiological mechanisms by which
sICAM-1 may promote mortality.
The pathophysiological pathway through which
sICAM-1 is associated with risk of cardiovascular mortal-
ity is unclear. The current theory is that increased plasma
concentrations of sICAM-1 reflect increased expression of
ICAM-1 on endothelial cells, smooth muscle cells and
monocytes, and thus may indicate progressive atherogen-
esis [1–4,9]. However, in our study high concentrations of
sICAM-1 were associated with an increased cardiovascular
mortality risk independent of (sub)clinical atherosclerosis,
as reflected by the presence of prior cardiovascular disease
and by the ankle-brachial pressure index. Therefore, it is
unlikely that high sICAM-1 concentrations exclusively
reflect progression of atherosclerosis.
Another hypothesis is that an increased concentration of
sICAM-1 is a marker of endothelial stimulation and (or) of
chronic, low-grade inflammation. Indeed, sICAM-1 levels
were significantly associated with von Willebrand factor
and (micro)albuminuria, i.e. potential markers of general-
ized endothelial stimulation that are associated with
cardiovascular disease [14,19,28–30], and with C-reactive
protein, a marker of inflammation [31,32]. However, our
data show that sICAM-1 was associated with cardiovas-
cular mortality independent of von Willebrand factor,
(micro)albuminuria and C-reactive protein [8], which
Figure 1 Percentage of subjects, with a normal glucose tolerance
(NGT), an impaired glucose tolerance (IGT) and with type 2
diabetes (DM), with a soluble intercellular adhesion molecule-1
(sICAM-1) concentration above 550 ng mL21. *Trend tested by
logistic regression analysis adjusted for age, sex and glucose status;
NGT  normal glucose tolerance; IGT  impaired glucose
tolerance; DM  type 2 diabetes.
Table 2 Soluble intercellular adhesion molecule-1 levels: associations with classical cardiovascular risk factors or indicators of
(sub)clinical atherosclerosis, endothelial function and inflammation
b* SE(b)* P-value
Gender (male vs. female) 2 8·49 13·15 0·519
Age (per 5-year increase) 2 6·19 4·635 0·182
Type 2 diabetes (yes vs. no) 76·69 15·89 , 0·001
Hypertension (yes vs. no) 41·94 13·93 0·003
Waist-to-hip ratio (per 0·01 increase) 3·05 0·99 0·002
Current smoking (yes vs. no) 61·44 14·51 , 0·001
HDL-cholesterol (per 0·1 mmol L21 increase) 2 4·20 2·00 0·036
Triglycerides (per 10% increase) ‡ 4·12 1·27 0·001
Von Willebrand factor (per 0·1 IU/mL increase) 2·08 0·97 0·032
C-reactive protein (per 10% increase) ‡ 2·47 0·51 , 0·001
sVCAM-1 (per 10% increase) ‡ 15·05 2·08 , 0·001
(Micro)albuminuria (yes vs. no)† 48·07 21·62 0·027
Prior cardiovascular disease (yes vs. no) † 47·57 15·72 0·003
Use of diabetes medication (yes vs. no) 24·65 54·45 0·66
HDL, high-density lipoprotein; sVCAM-1, soluble vascular cell adhesion molecule 1.
*Regression coefficient (b), standard error (SE[b]) and P-value obtained by linear regression analysis with sICAM-1 levels as dependent
variable and risk factors or indicators as independent variables, all adjusted for age, sex and glucose tolerance status (unless this was the
variable under consideration).
†Defined as described in legend to Table 1.
‡Log-transformed.
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argues against the hypothesis of sICAM-1 being a marker
of endothelial stimulation or inflammatory activity.
An alternative hypothesis is that a high sICAM-1 level
reflects a general increase in the expression of adhesion
molecules. We tested this concept by adjusting for levels
of sVCAM-1, which has also been found to be associated
with cardiovascular mortality [18,33]. We found that
sICAM-1 was indeed associated with sVCAM-1. How-
ever, the association between sICAM-1 and cardiovas-
cular mortality was hardly altered by correction for
sVCAM-1. This suggests that sICAM-1 acts differently
from sVCAM-1 in promoting atherothrombosis. ICAM-1
is expressed constitutively and has a broader expression
than VCAM-1 [5]. In reaction to inflammatory cytokines
such as interleukin-1 (IL-1) and tumour necrosis factor-a
(TNF-a), ICAM-1 is up-regulated on most tissues in
acute and inflammatory diseases. In addition, ICAM-1
expression in human aortic smooth muscle cells peaks
much more rapidly than VCAM-1 expression after
stimulation by TNF-a or IL-1 [34]. ICAM-1 and
VCAM-1 are both ligands for integrins on lymphocytes
and monocytes, but only ICAM-1 is a ligand for
neutrophils as well [5,35]. Therefore, sVCAM-1 and
sICAM-1 may be related to cardiovascular disease
through different pathways.
Finally, we examined whether renal dysfunction influ-
enced the association between sICAM-1 and cardiovas-
cular mortality, because levels of sICAM-1 were strongly
associated with serum creatinine levels among subjects
with chronic renal failure not receiving dialysis [36,37].
However, renal function was not associated with sICAM-1
in our study, nor did it influence the association between
sICAM-1 and cardiovascular mortality.
In short, we examined several possible pathophysiologi-
cal pathways that might explain the association between
sICAM-1 and cardiovascular mortality. Our findings
provide no evidence in favour of any of these hypotheses.
We conclude from this that sICAM-1 is independently
associated with cardiovascular mortality because it might
reflect, or may be involved in, instability of atherosclerotic
Figure 2 Cardiovascular survival (Kaplan–Meier curves)
according to plasma soluble intercellular adhesion molecule-1
(sICAM-1) concentration in the lowest (1), two middle (2 and 3)
and highest (4) quartile. *Logrank test for difference in survival
for different quartiles.
Table 3 Relative risk of cardiovascular and all-cause mortality associated with plasma concentrations of soluble intracellular adhesion
molecule-1 (sICAM-1)
Model Added variables
Cardiovascular mortality (n  43)
RR (95% CI)*
All-cause mortality (n  117)
RR (95% CI)*
1 Age, sex, glucose tolerance status 2·05 (1·10–3·81) 1·43 (0·96–2·13)
2 Model 1 and hypertension 1·98 (1·06–3·70) 1·39 (0·93–2·08)
3 Model 1 and HDL †, total cholesterol and triglycerides† 2·04 (1·10–3·80) 1·37 (0·91–2·07)
4 Model 1 and creatinine clearance† 2·05 (1·10–3·81) 1·42 (0·96–2·12)
5 Model 1 and glomerular filtration rate† 2·16 (1·17–4·03) 1·52 (1·02–2·28)
6 Model 1 and body mass index † 1·96 (1·05–3·68) 1·42 (0·93–2·16)
7 Model 1 and waist-to-hip ratio† 1·96 (1·05–3·68) 1·41 (0·94–2·11)
8 Model 1 and prior cardiovascular disease† 2·13 (1·14–3·97) 1·41 (0·94–2·10)
9 Model 1 and ankle-brachial pressure index† 2·06 (1·11–3·82) 1·43 (0·96–2·13)
10 Model 1 and current smoking 1·86 (0·98–3·52) 1·29 (0·86–1·94)
11 Model 1 and glycated haemoglobin 2·03 (1·09–3·79) 1·40 (0·94–2·10)
12 Model 1 and microalbuminuria† 1·92 (1·03–3·59) 1·40 (0·93–2·11)
13 Model 1 and von Willebrand factor† 2·10 (1·13–3·90) 1·42 (0·95–2·12)
14 Model 1 and C-reactive protein† 1·95 (1·05–3·63) 1·34 (0·91–1·99)
15 Model 1 and sVCAM-1 1·75 (0·91–3·34) 1·38 (0·91–2·08)
16 Model 1 and use of diabetes medication 2·09 (1·12–3·90) 1·42 (0·95–2·13)
All subjects (n  608).
HDL, high-density lipoprotein; sVCAM-1, soluble vascular cell adhesion molecule 1.
*Relative risk (95% confidence interval) of mortality associated with the upper as compared to the lower quartiles of soluble
intercellular adhesion molecule-1 (sICAM-1) concentration, as obtained with Cox multiple regression analyses. Model 1: adjusted for
stratification variables; Model 2–15: as Model 1, plus adjusted for other potential risk factors or risk indicators associated with
cardiovascular mortality.
†Defined as described in legend to Table 1
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plaques and (or) a prothrombotic state [10]. These issues
clearly need further investigation.
A high sICAM-1 level occurred significantly more often
among subjects with type 2 diabetes than among subjects
with a normal glucose tolerance [12,25,38]. We found that
the association between sICAM-1 and cardiovascular
mortality was similar in individuals without and with
type 2 diabetes, but the latter more often had high sICAM-
1 levels. These findings suggest that the pathophysiological
mechanism(s) reflected by sICAM-1 levels operate fre-
quently in individuals with type 2 diabetes and may thus be
involved in their increased risk of atherothrombotic
disease.
A limitation of the present study may be that concentra-
tions of sICAM-1 were measured only once, although in
duplicate, which might have led to nondifferential mis-
classification and consequently to underestimation of the
relative risk of mortality.
In conclusion, a high plasma concentration of sICAM-1
doubles the risk of cardiovascular mortality. This associa-
tion is largely independent of established cardiovascular
risk factors and indicators. The prevalence of a high
sICAM-1 concentration is significantly higher among
individuals with type 2 diabetes than among individuals
with a normal glucose tolerance. The present study
suggests that sICAM-1 concentrations could be used as
a tool in estimating the risk of future cardiovascular
mortality. Therapeutic options to lower sICAM-1 and
ICAM-1 already exist [10]. However, more work is
necessary to establish whether lowering the levels of
sICAM-1 decreases the risk of cardiovascular mortality.
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